On August 22, 2025, Xilio Therapeutics, Inc. received a letter from NASDAQ stating it does not meet the $10 million stockholders' equity requirement, reporting only $7.069 million. The company has 45 days to submit a plan to regain compliance; failure to do so may affect its listing.